U.S. Markets closed

Johnson & Johnson Analysts Laud Accelerating Pharma Business

Shanthi Rexaline

Pharma giant Johnson & Johnson (NYSE: JNJ) hosted a review of its pharmaceutical businesses Wednesday, and analysts came away largely impressed.

The Analysts

Morgan Stanley analyst David Lewis maintained an Equal-weight rating on Johnson & Johnson with a $145 price target.

BMO Capital Markets analyst Joanne Wuensch reiterated an Outperform rating and $157 price target.

Morgan Stanley: J&J Story Looks Brighter

J&J expressed confidence in the acceleration of its pharma business in 2020, with the segment likely to see above-market growth through 2023, Lewis said in a Thursday note.

The analyst models about 7-percent growth for the segment in 2020, up from 4-percent growth in 2019.

The acceleration is premised Johnson & Johnson emerging from 2019 headwinds, increased pipeline contributions, indication expansion for current blockbuster franchises and the absence of any major patent/exclusivity expirations in the near-term, Lewis said. 

"2019 could see a near perfect storm of Pharma headwinds but moving past these, acceleration is likely and could drive stock performance," the analyst said. 

J&J expects at least 10 new blockbuster approvals and filings from 2019-2023 — including the recently launched Spravato and Balversa — and 10 potential 2019-2023 filings, according to Morgan Stanley. 

"In addition to this, the company highlighted at least 40 line extensions for current franchises, including over 10 with $500mn potential," Lewis said. 

Morgan Stanley expects consensus estimates to move higher for the stock. 

See also: The Daily Biotech Pulse: FDA Nod For Roche, Trial Results For Agios, Iovance And MacroGenics

BMO: J&J Continues To Innovate

J&J's discipline to acquire and divest assets in its health care portfolio, its pristine balance sheet and its high dividend yield make the stock a strong defensive choice, Wuensch said in a Wednesday note. 

The following are the analyst's key takeaways from the event:

• Stelara is the company's largest asset, contributing in the psoriasis and Crohn's disease markets.
• Tremfya, a selective IL 23 inhibitor for psoriasis, is delivering more than $500 million in global sales in its first year.
• Darzalex is redefining multiple myeloma treatment, including combo therapies.
• Imbruvica is defining a new standard-of-care in chronic lymphocytic leukemia.
• J&J is leveraging its Actelion acquisition for pulmonary hypertension management.
• The recently approved Spravato has a vast market opportunity in treatment-resistant depression.

"Despite the concerns of pricing pressure and generic and biologic competition, J&J continues to do what it does best, innovate," Wuensch said. 

The Price Action

J&J shares, which have gained roughly 7 percent year-to-date, were trading up 1.04 percent at $138.31 at the time of publication Thursday. 

Related Link: Advaxis Shares Climb After FDA Lifts Partial Clinical Hold On Cervical Cancer Drug

Photo courtesy of Johnson & Johnson. 

Latest Ratings for JNJ

Date Firm Action From To
May 2019 Maintains Outperform
Apr 2019 Maintains Outperform Outperform
Apr 2019 Maintains Outperform Outperform

View More Analyst Ratings for JNJ
View the Latest Analyst Ratings

See more from Benzinga

© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.